Is there a generic for tagrisso?

When does a generic version of Tagrisso become available?

As of my knowledge cutoff in 2023, Tagrisso (osimertinib) is a prescription medication developed by AstraZeneca [1]. The original patent for Tagrisso was initially set to expire in 2027, but it has been subject to multiple patent extensions and challenges [2]. Given the complexity of pharmaceutical patent law, the exact date for the patent expiration is difficult to predict, and any extension may further delay the entry of generics.

How do generics enter the market?

In the United States, the FDA requires generics to show bioequivalence to the brand-name drug in clinical trials [3]. Once a generic manufacturer receives approval and launches a generic version of Tagrisso, it will be marketed under a different name. However, until the original patent expires, it is challenging for generic manufacturers to enter the market.

Current generic alternatives

As of my knowledge cutoff in 2023, there are no approved generic versions of Tagrisso available on the market in the United States. However, several manufacturers are developing biosimilars – a type of biologic medication highly similar to the original version – which are subject to different regulatory paths.

Biosimilar alternatives

Biosimilars are not exact copies of the original medication but are similar enough to be interchangeable in most cases. AstraZeneca's Tagrisso was not eligible for traditional generic approval due to its complex molecular structure. Nevertheless, biosimilars for osimertinib might become available in the future, offering more affordable options for patients.

Timeline and regulation

Regulatory agencies like the FDA continuously evaluate the patent status of brand-name medications and assess the entry of generics and biosimilars. Patients seeking affordable options are advised to check the FDA's website for updates on Tagrisso's patent status and any approved generic or biosimilar alternatives.

Sources:

[1] https://www.drugs.com/tagrisso.html (Tagrisso on Drugs.com)

[2] https://www.drugpatentwatch.com/DrugPatent/Tagrisso (Tagrisso patent information on DrugPatentWatch.com)

[3] https://www.fda.gov/drugs/guidance-compliance-regulatory-information/biosimilars/guidance-manufacturers-biosimilar-applications (FDA guidelines for biosimilar applications)